Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says

MT Newswires Live01-07

Regeneron Pharmaceuticals (REGN)'s Eylea HD has had some recent label updates, including an approval by the US Food and Drug Administration for the treatment of retinal vein occlusion, BofA Securities said Wednesday.

BofA also expects an FDA approval for Eylea HD's pre-filled syringe, or PFS, in mid-2026. Larger practices could use HD over Vabysmo, and biosimilars do not impact its demand, BofA said. The firm expects US Eylea franchise revenue of $4.35 billion in 2026, versus consensus estimate of $3.86 billion.

The company's anti-inflammatory drug Dupixent is demonstrating growth in atopic dermatitis and asthma. Other launches by Regeneron are also showing progress and can support reliable franchise growth, the brokerage said. For 2026, BofA models Dupixent revenue of $20.7 billion, same as market consensus.

Regeneron has yet to reach an agreement on the Most Favored Nation drug pricing deal with the White House, which BofA views as an important catalyst in early 2026. The brokerage is also looking forward to the company's clinical trials for oncology and other indications in the first half of 2026.

BofA upgraded Regeneron shares to buy from underperform and raised its price target to $860 from $627.

Shares of the company rose by more than 3% in recent Wednesday trading.

Price: 799.05, Change: +22.51, Percent Change: +2.90

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601029048?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 23:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601029048","market":"hk","top_or_hot":-1,"title":"Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says","media":"MT Newswires Live","content":"<html><body><p> Regeneron Pharmaceuticals (REGN)'s Eylea HD has had some recent label updates, including an approval by the US Food and Drug Administration for the treatment of retinal vein occlusion, BofA Securities said Wednesday.</p><p>BofA also expects an FDA approval for Eylea HD's pre-filled syringe, or PFS, in mid-2026. Larger practices could use HD over Vabysmo, and biosimilars do not impact its demand, BofA said. The firm expects US Eylea franchise revenue of $4.35 billion in 2026, versus consensus estimate of $3.86 billion.</p><p>The company's anti-inflammatory drug Dupixent is demonstrating growth in atopic dermatitis and asthma. Other launches by Regeneron are also showing progress and can support reliable franchise growth, the brokerage said. For 2026, BofA models Dupixent revenue of $20.7 billion, same as market consensus.</p><p>Regeneron has yet to reach an agreement on the Most Favored Nation drug pricing deal with the White House, which BofA views as an important catalyst in early 2026. The brokerage is also looking forward to the company's clinical trials for oncology and other indications in the first half of 2026.</p><p>BofA upgraded Regeneron shares to buy from underperform and raised its price target to $860 from $627.</p><p>Shares of the company rose by more than 3% in recent Wednesday trading.</p><p>Price: 799.05, Change: +22.51, Percent Change: +2.90</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-07 23:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Regeneron Pharmaceuticals (REGN)'s Eylea HD has had some recent label updates, including an approval by the US Food and Drug Administration for the treatment of retinal vein occlusion, BofA Securities said Wednesday.</p><p>BofA also expects an FDA approval for Eylea HD's pre-filled syringe, or PFS, in mid-2026. Larger practices could use HD over Vabysmo, and biosimilars do not impact its demand, BofA said. The firm expects US Eylea franchise revenue of $4.35 billion in 2026, versus consensus estimate of $3.86 billion.</p><p>The company's anti-inflammatory drug Dupixent is demonstrating growth in atopic dermatitis and asthma. Other launches by Regeneron are also showing progress and can support reliable franchise growth, the brokerage said. For 2026, BofA models Dupixent revenue of $20.7 billion, same as market consensus.</p><p>Regeneron has yet to reach an agreement on the Most Favored Nation drug pricing deal with the White House, which BofA views as an important catalyst in early 2026. The brokerage is also looking forward to the company's clinical trials for oncology and other indications in the first half of 2026.</p><p>BofA upgraded Regeneron shares to buy from underperform and raised its price target to $860 from $627.</p><p>Shares of the company rose by more than 3% in recent Wednesday trading.</p><p>Price: 799.05, Change: +22.51, Percent Change: +2.90</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2106854487.HKD","symbol_name":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601029048","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601029048","pubTimestamp":1767801268,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regeneron Pharmaceuticals (REGN)'s Eylea HD has had some recent label updates, including an approval by the US Food and Drug Administration for the treatment of retinal vein occlusion, BofA Securities","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","REGN":"再生元制药公司","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4139":"生物科技"},"translate_title":"美国银行表示，再生元制药将在2026年进行多项管道更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1.5},"content_text":"Regeneron Pharmaceuticals (REGN)'s Eylea HD has had some recent label updates, including an approval by the US Food and Drug Administration for the treatment of retinal vein occlusion, BofA Securities said Wednesday.BofA also expects an FDA approval for Eylea HD's pre-filled syringe, or PFS, in mid-2026. Larger practices could use HD over Vabysmo, and biosimilars do not impact its demand, BofA said. The firm expects US Eylea franchise revenue of $4.35 billion in 2026, versus consensus estimate of $3.86 billion.The company's anti-inflammatory drug Dupixent is demonstrating growth in atopic dermatitis and asthma. Other launches by Regeneron are also showing progress and can support reliable franchise growth, the brokerage said. For 2026, BofA models Dupixent revenue of $20.7 billion, same as market consensus.Regeneron has yet to reach an agreement on the Most Favored Nation drug pricing deal with the White House, which BofA views as an important catalyst in early 2026. The brokerage is also looking forward to the company's clinical trials for oncology and other indications in the first half of 2026.BofA upgraded Regeneron shares to buy from underperform and raised its price target to $860 from $627.Shares of the company rose by more than 3% in recent Wednesday trading.Price: 799.05, Change: +22.51, Percent Change: +2.90","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601029048","isCrawlerRequest":true}